Stoke Therapeutics (STOK) Change in Accured Expenses (2018 - 2026)

Stoke Therapeutics' Change in Accured Expenses history runs 9 years deep, the most recent figure standing at -$15.7 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 431.55% year-over-year to -$15.7 million; the TTM figure through Mar 2026 stood at $829000.0 (down 91.5% YoY), while the FY2025 annual figure was $21.3 million, up 589.41% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$15.7 million, down from $8.9 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $8.9 million in Q4 2025, with the low at -$15.7 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $351000.0 (2023), against an average of $112941.2.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses slumped 677.39% in 2023, then jumped 751.67% in 2025.
• Stoke Therapeutics' Change in Accured Expenses stood at $199000.0 in 2022, then plunged by 677.39% to -$1.1 million in 2023, then surged by 289.64% to $2.2 million in 2024, then soared by 308.54% to $8.9 million in 2025, then plunged by 276.58% to -$15.7 million in 2026.
• Business Quant data shows STOK's Change in Accured Expenses at -$15.7 million in Q1 2026, $8.9 million in Q4 2025, and $4.9 million in Q3 2025.